Download PDF
Geburtshilfe Frauenheilkd 2022; 82(01): 34-38
DOI: 10.1055/a-1430-4878
GebFra Magazin
Aktuell diskutiert

Mit Morbus Crohn und Colitis ulcerosa sicher durch die Schwangerschaft

Miriam Wiestler
,
Ursula Seidler
› Further Information
Also available at
    Permissions and Reprints

Aufgrund des mehrheitlich jungen Erkrankungsalters befinden sich PatientInnen mit chronisch entzündlichen Darmerkrankungen (CED) oft in der Phase der Kinderplanung. Auch wenn die Rate an Kinderlosigkeit unter CED-PatientInnen im Vergleich zur Normalbevölkerung erhöht ist, kann die Fertilität im Erkrankungsschub oder nach besonderen Situationen wie bspw. Beckenoperationen eingeschränkt sein. Dies verdeutlicht, dass CED-PatientInnen sich eher aufgrund ihrer Erkrankung einer freiwilligen Kinderlosigkeit oder -armut unterwerfen. Das muss nicht sein. Im Folgenden werden Maßnahmen zur Minimierung von Komplikationen und Kontrolle der Inflammationsaktivität beschrieben, denn das Erreichen einer stabilen Remission vor der Konzeption und während der gesamten Schwangerschaft ist der wichtigste Faktor, um das Risiko von Komplikationen während der Schwangerschaft so gering wie möglich zu halten.

Publication History

Article published online:
10 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Molodecky NA, Soon IS, Rabi DM. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42
    CrossrefPubMedSearch in Google Scholar
  • 2 Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 591-599
    CrossrefPubMedSearch in Google Scholar
  • 3 Selinger CP, Eaden J, Selby W. et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 2013; 7: e206-e213
    CrossrefPubMedSearch in Google Scholar
  • 4 Ørding Olsen K, Juul S, Berndtsson I. et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122: 15-19
    CrossrefPubMedSearch in Google Scholar
  • 5 Loftus EVJ. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517
    CrossrefPubMedSearch in Google Scholar
  • 6 Orholm M, Fonager K, Sørensen HT. Risk of ulcerative colitis and Crohn’s disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3236-3238
    CrossrefPubMedSearch in Google Scholar
  • 7 van der Woude CJ, Ardizzone S, Bengtson MB. et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9: 107-124
    CrossrefPubMedSearch in Google Scholar
  • 8 Akolkar PN, Gulwani-Akolkar B, Heresbach D. et al. Differences in risk of Crohn’s disease in offspring of mothers and fathers with inflammatory bowel disease. Am J Gastroenterol 1997; 92: 2241-2244
    PubMedSearch in Google Scholar
  • 9 Zelinkova Z, Stokkers PC, van der Linde K. et al. Maternal imprinting and female predominance in familial Crohn’s disease. J Crohns Colitis 2012; 6: 771-776
    CrossrefPubMedSearch in Google Scholar
  • 10 Laharie D, Debeugny S, Peeters M. et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120: 816-819
    CrossrefPubMedSearch in Google Scholar
  • 11 Bush MC, Patel S, Lapinski RH. et al. Perinatal outcomes in inflammatory bowel disease. J Matern neonatal Med 2004; 15: 237-241
    CrossrefPubMedSearch in Google Scholar
  • 12 Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989; 160: 998-1001
    CrossrefPubMedSearch in Google Scholar
  • 13 Nielsen OH, Andreasson B, Bondesen S. et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735-742
    CrossrefPubMedSearch in Google Scholar
  • 14 Morales M, Berney T, Jenny A. et al. Crohn’s disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology 2000; 47: 1595-1598
    PubMedSearch in Google Scholar
  • 15 Beniada A, Benoist G, Maurel J. et al. Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature. J Gynecol Obstet Biol Reprod (Paris) 2005; 34: 581-588
    CrossrefPubMedSearch in Google Scholar
  • 16 German Society for Digestive and Metabolic Diseases (DGVS)>. Updated S3-Guideline Ulcerative Colitis. Z Gastroenterol 2019; 57: 162-241
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Ma T, Yin X, Han R. et al. Effects of In Utero Exposure to Di-n-Butyl Phthalate on Testicular Development in Rat. Int J Environ Res Public Health 2017; 14: 1284
    CrossrefPubMedSearch in Google Scholar
  • 18 Carmichael SL, Shaw GM, Ma C. et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197: 585.e1-585.e7
    CrossrefPubMedSearch in Google Scholar
  • 19 Coelho J, Beaugerie L, Colombel JF. et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203
    CrossrefPubMedSearch in Google Scholar
  • 20 Kozlowski RD, Steinbrunner J V, MacKenzie AH. et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589-592
    CrossrefPubMedSearch in Google Scholar
  • 21 Julsgaard M, Christensen LA, Gibson PR. et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016; 151: 110-119
    CrossrefPubMedSearch in Google Scholar
  • 22 Wagner N, Assmus F, Arendt G. et al. Impfen bei Immundefizienz. Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2019; 62: 494-515
    CrossrefPubMedSearch in Google Scholar
  • 23 Moens A, van der Woude CJ, Julsgaard M. et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 2020; 51: 129-138
    CrossrefPubMedSearch in Google Scholar